No mutations were detected in POLE or POLD1 that might confer sensitivity to immunotherapy.8 There was no monosomy of chromosome 22q and none of the most commonly encountered pathogenic variants in meningiomas were encountered, including CDKN2A/B, the TERT promoter, SMO, AKT1, PIK3CA, PIK3R1, TRAF7, KLF4, SUFU, ARID1A, SMARCB1, BAP1, POLR2A, SMARCE1, or NF2,9 although NF2 deletion and/or chromosome 22q loss are only seen in 50%–60% of menigniomas.10–12 Furthermore, multiple copy number losses were noted, including loss of chromosomes 1p, distal 2p, 3p, 4p, distal 7p, distal 7q, 11p, and 12p. This evidence concerns the gene NF2 and meningioma.